Under the terms of this collaboration, Abbott will pay Celera an undisclosed fee to perform this study and any resulting companion diagnostic product could be developed by Celera and commercialized through its existing strategic alliance with Abbott.
“We’re pleased to enter this collaboration with Abbott as it further reinforces Celera’s commitment to personalized medicine,” said Thomas White, Ph.D., Chief Scientific Officer at Celera. “The results of this study will provide new information on the correlation between genetic markers associated with disease and response to therapy. Routinely testing this general concept in early clinical trials may give us new and important insights to personalizing disease management.”
About Celera
Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “should,” “anticipate,” and “intend,” among others. These forward-looking statements are based on Celera’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Celera notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera’s business include but are not limited to: (1) unproven ability of Abbott and Celera to successfully manage and operate the collaboration; (2) the risk that products developed under this collaboration, if any, will not advance as anticipated, or may not receive required regulatory clearances or approvals; (3) the uncertainty that any products developed under the collaboration be accepted and adopted by the market, including the risk that these products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for these products from third party payors such as private insurance companies and government insurance plans; and (4) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Celera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Copyright© 2008. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries.
Contact:
Celera Corporation David Speechly, Ph.D. 510-749-1853 David.Speechly@celera.com
Source: Celera Corporation
